2026-10-19T01:08:24Zhttps://ebyu-rdlopen.rawdatalibrary.net/oai/request

oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/119822026-10-18T21:13:22Zopenairedrivercom_ebyu_10000col_ebyu_10001

Correction to: PrevAleNce and Associated factors of inappropriaTe dosing of direct Oral anticoaguLants In pAtients with Atrial Fibrillation: the ANATOLIA-AF Study (Cardiovascular Drugs and Therapy, (2024), 38, 3, (581-599), 10.1007/s10557-022-07409-w)Kocabaş, UmutErgin, IsilYavuz, VeyselMurat, SeldaÖzdemir, IbrahimGenç, ÖmerAltın, CihanTüner, HaşimMeriç, Bengisu KeskinÇoner, AliYüce, Elif İlkayBoyraz, BedrettinAslan, OnurDal, AhmetŞen, Tanerİbişoğlu, ErsinErdoğan, AslanÖzgeyik, MehmetDemir, MevlütBilgel, Ziya GökalpŞengör, Büşra GüvendiUrgun, Örsan DenizDoğduş, MustafaTekin, Deniz Dilan NakiÇakal, SinemÇayırlı, SercanGüler, ArdaKarabulut, DilayDalgıç, OnurUzman, OsmanMurat, BektaşŞahin, ŞeydaKarabulut, UmutKıvrak, TarıkCoşgun, Muharrem SaidÖzyurtlu, FerhatKaplan, MehmetÖzçalık, EmreerratumIn the following article published in Cardiovascular Drugs and Therapy, December 17, 2022, the subtitle of Table 1 included an incorrect phrase: “For patients receiving rivaroxaban or for patients receiving apixaban or for patients receiving edoxaban.” (Table presented.) Criteria for defining a patient as requiring a reduced dose of direct oral anticoagulants in the ANATOLIA-AF study For patients receiving dabigatran • Age ≥ 80 years • Concomitant usage of verapamil • ≥ 2 of the following criteria: age 75–79 years, GFR 30–50 mL/min/1.73 m2, HAS-BLED score ≥ 3, concomitant usage of antiplatelet therapy, concomitant usage of amiodarone, or body weight ≤ 60 kg For patients receiving rivaroxaban • GFR 15–49 mL/min/1.73 m2 • ≥ 2 of the following criteria: age ≥ 75 years, HAS-BLED score ≥ 3, concomitant usage of antiplatelet therapy, concomitant usage of amiodarone, or body weight ≤ 60 kg For patients receiving apixaban • ≥ 2 of the following criteria: age ≥ 80 years, serum creatinine ≥ 1.5 mg/dL, or body weight ≤ 60 kg • GFR 15–29 mL/min/1.73 m2 • ≥ 2 of the following criteria: age ≥ 75 years, HAS-BLED score ≥ 3, concomitant usage of antiplatelet therapy, concomitant usage of amiodarone, or concomitant usage of diltiazem For patients receiving edoxaban • GFR 15–49 mL/min/1.73 m2 • Body weight ≤ 60 kg • Concomitant usage of strong P-glycoprotein inhibitor (e.g., dronedarone, ketoconazole, erythromycin) • ≥ 2 of the following criteria: age ≥ 75 years, HAS-BLED score ≥ 3, concomitant usage of antiplatelet therapy, concomitant usage of amiodarone, or concomitant usage of verapamil GFR glomerular filtration rate, HAS-BLED uncontrolled hypertension, abnormal renal and liver function (1 point each), stroke, bleeding, labile international normalized ratios, elderly (age > 65 years), drugs or alcohol (1 point each) (concomitant use of antiplatelet agents or non-steroidal anti-inflammatory drugs, alcohol abuse). This has been deleted and replaced with the correction subheading “For patients receiving dabigatran.” Below is Table 1 including this correction. © Springer Science+Business Media, LLC, part of Springer Nature 2023.Springer2024Correctionhttps://rdlopen.rawdatalibrary.net/r/ebyu/11982https://doi.org/10.1007/s10557-023-07427-20920-3206enCardiovascular Drugs and Therapyinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/articlehttps://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/11982